TCGA-AC-A8OQ-01A-11R-A41B-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 1
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.370
- ALLOGRAFT_REJECTION+0.360
- IL6_JAK_STAT3_SIGNALING+0.330
- INTERFERON_GAMMA_RESPONSE+0.330
- INTERFERON_ALPHA_RESPONSE+0.320
- APICAL_JUNCTION+0.300
- INFLAMMATORY_RESPONSE+0.290
- MYOGENESIS+0.250
- TNFA_SIGNALING_VIA_NFKB+0.230
- COAGULATION+0.210
Top 10 suppressed
- PROTEIN_SECRETION-0.510
- ESTROGEN_RESPONSE_EARLY-0.410
- ESTROGEN_RESPONSE_LATE-0.370
- ANDROGEN_RESPONSE-0.320
- UV_RESPONSE_DN-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
- PEROXISOME-0.260
- DNA_REPAIR-0.180
- TGF_BETA_SIGNALING-0.180
- MTORC1_SIGNALING-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-S3-AA15-01A-11R-A41B-07 | — | D | 0.879 |
| 2 | MBCProject_7544_T1_RNA | — | D | 0.877 |
| 3 | TCGA-EW-A3U0-01A-11R-A22K-07 | — | D | 0.858 |
| 4 | TCGA-A2-A3XY-01A-11R-A239-07 | — | D | 0.848 |
| 5 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.848 |
| 6 | MBCProject_0582_T1_RNA | — | D | 0.836 |
| 7 | AUR-AFR5-TTP1-A-1-1-R-A743-41 | — | D | 0.814 |
| 8 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.799 |
| 9 | SRR25617829 | — | D | 0.797 |
| 10 | TCGA-GM-A2DF-01A-11R-A180-07 | — | E | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |